You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科笛-B(02487.HK)治療脫髮及痤瘡藥物臨床試驗達到主要終點指標
阿思達克 12-11 08:30
科笛-B(02487.HK)公布,集團治療雄激素性脫髮產品CU-40102(外用非那雄胺噴霧劑)及治療非結節性中度至重度尋常痤瘡產品CU-10201(外用4%米諾環素泡沫劑)的中國III期臨床試驗結果,在第十八屆中國醫師協會皮膚科醫師年會暨全國美容皮膚科學大會上發布。 CU-40102臨床試驗結果顯示,在療效方面,受試者在治療24周後,CU-40102組受試者的頂部禿髮目標區域內的總毛髮計數及終毛計數改善均顯著優於安慰劑組,差異具有統計學意義(P <0.05),達到主要終點指標和主要的次要終點指標,且療效從第12周起開始展現。 CU-10201臨床試驗結果顯示,在療效方面,受試者在治療12周後,CU-10201組炎性皮損的改善顯著優於安慰劑組,差異具有統計學意義(P <0.001),達到主要終點指標。優於安慰劑組的療效差異在第四周後開始顯示,且隨著給藥時間延長,CU-10201組中顯示的療效逐漸增加。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account